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Background: While there is strong evidence for phosphatidylinositol 3-kinase (PI3K) involvement in cancer
development, there is limited information about the role of PI3K regulatory subunits. PIK3R3, the gene that encodes
the PI3K regulatory subunit p55γ, is over-expressed in glioblastoma and ovarian cancers, but its expression in gastric
cancer (GC) is not known. We thus used genetic and bioinformatic approaches to examine PIK3R3 expression and
function in GC, the second leading cause of cancer mortality world-wide and highly prevalent among Asians.
Methods: Primary GC and matched non-neoplastic mucosa tissue specimens from a unique Asian patient gastric
cancer library were comprehensively profiled with platforms that measured genome-wide mRNA expression, DNA
copy number variation, and DNA methylation status. Function of PIK3R3 was predicted by IPA pathway analysis of
co-regulated genes with PIK3R3, and further investigated by siRNA knockdown studies. Cell proliferation was
estimated by crystal violet dye elution and BrdU incorporation assay. Cell cycle distribution was analysed by FACS.
Results: PIK3R3 was significantly up-regulated in GC specimens (n = 126, p < 0.05), and 9.5 to 15% tumors showed
more than 2 fold increase compare to the paired mucosa tissues. IPA pathway analysis showed that PIK3R3
promoted cellular growth and proliferation. Knockdown of PIK3R3 decreased the growth of GC cells, induced
G0/G1 cell cycle arrest, decreased retinoblastoma protein (Rb) phosphorylation, cyclin D1, and PCNA expression.
Conclusion: Using a combination of genetic, bioinformatic, and molecular biological approaches, we showed that
PIK3R3 was up-regulated in GC and promoted cell cycle progression and proliferation; and thus may be a potential
new therapeutic target for GC.Background
Class IA Phosphatidylinositol 3’-kinases (PI3K) is a het-
erodimer that consists of a p110 catalytic subunit and a
p85 regulatory subunit. The catalytic subunit isoforms
p110α, p110β and p110δ are encoded by three genes —
PIK3CA, PIK3CB and PIK3CD, respectively [1]. The role
of catalytic subunits in a wide range of cellular processes
associated with cancer development and progression is
well established [2]. The PIK3CA gene is one of the best* Correspondence: paul.yen@duke-nus.edu.sg
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reproduction in any medium, provided the orstudied oncogenes, and is amplified, overexpressed, or
frequently mutated in many cancers, including GC [2,3].
PIK3CB is the principal isoform involved in mediating
PTEN-deficient tumourigenesis [4]. In addition, PIK3CD
has also emerged as a key therapeutic target for haemato-
logical malignancies [5], notably acute myeloid leukaemia
(AML). Consequently, targeting catalytic subunits repre-
sents an important strategy for the development of novel
cancer therapeutics.
In contrast, current understanding of the role of regu-
latory subunits in tumorigenesis has been limited. Three
genes, PIK3R1, PIK3R2 and PIK3R3, encode the p85α,
p85β and p55γ isoforms of the p85 regulatory subunit,
respectively [6]. PIK3R1, the inhibitory subunit of PI3K,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumors [7,8], and ectopic expression of some of those
mutations increased the pAKT level in U2OS cells. Inter-
estingly, PIK3R3 has increased expression in glioblast-
oma multiforme and ovarian cancer [9,10]. Knockdown
of PIK3R3 inhibits IGF2-induced cell growth in glioblast-
oma multiforme [9] and induces apoptosis in ovarian
cancer cells [10]. Taken together, these results suggest an
oncogenic role for PIK3R3 in these cancers.
GC is the second leading cause of global cancer mortal-
ity and is highly prevalent among Asians [11]. Most GC
patients are diagnosed with late stage disease and the over-
all 5-year survival rate is <24% [12-14]. Deregulation of ca-
nonical oncogenic pathways such as E2F, K-RAS, p53, and
Wnt/b-catenin signaling are known to occur with varying
frequencies in GC [15-17], suggesting that GC is a hetero-
geneous disease with multiple molecular defects. Al-
though PIK3R3 is overexpressed in several cancers,
little is known about the expression and functional role of
PIK3R3 in GC. To address these issues, we used genetic
and bioinformatic approaches to interrogate a unique li-
brary of 126 paired GC samples and matched non-
neoplastic mucosa tissues from Asian GC patients.
Methods
Human cancer specimens and cell lines
We created a library of 126 primary gastric tumors
and their matched non-neoplastic mucosa tissues from
126 Asian patients that were originally stored at the
SingHealth Tissue Repository, an institutional resource
of National Cancer Centre of Singapore and Singapore
General Hospital. All patient samples were obtained
with informed patient consent and approvals from In-
stitutional Review Boards and Ethics Committees. GC
cell lines HGC-27, KATO III, AGS cells were pur-
chased from the American Type Culture Collection.
MKN7, TMK1 and IM95 cells were obtained from the
Japan Health Science Research Resource Bank. Cell
lines were maintained in a humidified atmosphere
containing 5% CO2 at 37°C. HGC-27, IM95 cells were
cultured in DMEM medium supplemented with 10%
FBS (Sigma); AGS, TMK1 and KATO III and MKN7
were cultured in RPMI 1640 medium supplemented
with 10% FBS.
Microarray Profiling & Pre-processing
Genomic DNA was extracted from flash-frozen tissues
using a Qiagen genomic DNA extraction kit. Total RNAs
was extracted using Trizol (Invitrogen, CA), digested
with RNase free DNase (RQ1 DNase, Promega), and sub-
sequently purified using an RNeasy Mini kit (Qiagen,
CA). Genome-wide mRNA expression was profiled using
Affymetrix GeneChip Human Genome U133 Plus 2.0
array. Copy number analysis was profiled usingAffymetrix Human SNP array 6.0. DNA methylation ana-
lysis was profiled using Illumina Infinium methylation
assay. Profiling on the individual microarray platforms was
done according to manufacturer’s specifications.
The raw microarray data was pre-processed using the
respective platform software from the manufacturer:
mRNA and SNP data using Affymetrix’s Genome Studio
and Genotyping Console respectively, and DNA methyla-
tion using Illumina’s BeadStudio. For SNP data, the normal
gastric samples were used as the reference for
normalization. The copy number segmentation was
generated using Circular Binary Segmentation (CBS) from
the R package DNA copy [18] using default settings.
Gene-based copy number alterations were obtained by
averaging the segments within each gene. Amplification
and deletion were called using the threshold of 0.3 and
−0.3 respectively [19].
The microarray data has been deposited into the
National Centre for Biotechnology Information’s (NCBI)
Gene Expression Omnibus (GEO) website, series accession
number GSE31168 (SNP6) and GSE15460 (mRNA).
PIK3R3 co-regulated gene and IPA pathway analysis
Co-regulated genes with PIK3R3 were elucidated using
Pearson correlation on the mRNA data. We focused
on probes that were specifically targeting the genes
(i.e., probes with suffix ‘_at’ and ‘_a_at’) and significant
correlation after correcting for multiple testing (p < 1e-5).
Pathways involving the probes were assessed using In-
genuity Pathway Analysis software (http://www.ingenuity.
com). All statistical analyses were computed using the R
statistical package.
RNA Extraction and RT-PCR
Total cellular RNA was isolated with the High Pure
RNA isolation Kit (Roche) following the manufacturer's
protocol and total RNA was quantified with a Nanodrop
ND-1000 spectrophotometer. Total RNA (1 μg) was
reverse-transcribed using iSCRIPT cDNA synthesis kit
(Bio-rad) under condtions defined by the supplier. cDNA
was quantified by real-time PCR on the Rotor-Gene Q
System (Qiagen). PIK3R3 forward primer: GAGAGGG
GAATGAAAAGGAGA, and reverse primer: ATCAT
GAATCTCACCCAGACG [10]. β-actin forward primer:
AGAGCCTCGCCTTTGCCGAT, and reverse primer: TT
GCACATGCCGGAGCCGTT; GAPDH forward primer:
TCTTTTGCGTCGCCAGCCGA, and reverse primer:
CCAGGCGCCCAATACGACCA. PCR was done using
QuantiFast SYBR Green PCR Kit (Qiagen) according to
manufacturer’s instructions.
To test the effect of LY294002 on PIK3R3 expression,
the complete medium was replaced by serum free medium
and LY294002 (20 μM/L, Sigma) was added. The total
RNA was extracted 24 h after LY294002 treatment.
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Two PIK3R3 siRNAs ordered from Santa Cruz (sc-39124)
or Invitrogen (s16152) were used to knock down PIK3R3
in GC cells. HGC-27 or TMK1 cells were seeded into 12
or 6-well plates in complete medium and cultured over-
night. Then the medium was replaced with opti-MEM
medium (Invitrogen) containing PIK3R3 or control siRNA
and Lipofectamine RNAimax (Invitrogen) according to the
manufacturer’s recommendations. 48 h after transfection,
cell lysates were prepared for Western blot analysis for de-
tection of PIK3R3 expression.
Cell proliferation assay
Cell proliferation assay was done as previously described
[20,21]. Briefly, 24 h after siRNA transfection, the HGC27
cells were trypsinized, resuspended in 1.1 ml complete cul-
ture medium, and re-seeded into 4 new 12-well plates at
250 μl per well. The cells were fixed 1 to 4 days after re-
seeding, respectively, and stained with crystal violet. Using
10% acetic acid, dye was extracted, and absorbance at
595 nm was measured using a multiwall spectrophotom-
eter (Bio-Rad).
Measurement of BrdU incorporation
48 h after siRNA transfection, HGC27 cells cultured in 6
well-plates were incubated with BrdU (10 μg/ml) for
7 min. The cells were detached, fixed and stained using
FITC BrdU Flow Kit (BD Pharmingen) following the
manufacturer's protocol. DNA synthesis was determined
by flow cytometer.
Annexin-V/propidium iodide staining
Annexin V staining was detected by flow cytometry using
the FITC Annexin V Apoptosis Detection Kit I (BD
Pharmingen). 48 h after siRNA transfection, Both float-
ing and adherent HGC27 cells were collected. Then the
cells were washed and stained following the manufac-
turer's protocol. Apoptotic cells were determined by flow
cytometer.
Cell cycle analysis
48 h after siRNA transfection, HGC-27 cells were harvested,
washed twice with cold phosphate buffered saline (PBS, pH
7.4), and fixed with 70% ethanol/30% PBS at 4°C overnight.
The fixed cells were incubated with 0.5 ml PBS containing
10 μg/ml RNase for 30 min at 37°C, then stained with
20 μg/ml propidium iodide (PI, Sigma) for 30 min in the
dark at room temperature, and finally analyzed on a FACS
cytometer (Beckman FC5000). A minimum of 1 × 104 cells/
sample was evaluated.
Western blot analysis
Cells were harvested, and lysed 48 h after siRNA trans-
fection. Proteins were separated by SDS–PAGE underreducing conditions and transferred to nitrocellulose mem-
branes. Membranes were blocked with 5% nonfat milk in
phosphate-buffered saline with 0.1% tween 20 (PBST), and
the membranes for PI3KR3 blot were blocked with 2%
gelatine, 0.2% FBS in PBST [22]. The blots were incu-
bated overnight at 4°C with the following antibodies:
anti-PIK3R3 antibody, anti-beta actin antibody (Santa
Cruz), anti-phospho-RB (Ser 780), anti-cyclin D1, anti-
phospho-p38 MAPK antibody (Thr180/Tyr 182), anti-
phospho-AKT (Ser 473), anti-phospho-AKT (Ser 308),
anti-phospho-m-TOR (Ser 2448) (Cell signaling Tech-
nology), anti-PCNA antibody (Millipore). Immunoblot
analysis was performed using an enhanced chemilu-
minescence procedure (GE Healthcare).
Results
PIK3R3 mRNA is over-expressed in a subgroup of GC
We examined the PIK3R3 mRNA expression of 126 gas-
tric adenocarcinoma samples and matched non-neoplastic
mucosa control gastric tissues, profiled on Affymetrix
GeneChip Human Genome U133 Plus 2.0 arrays. We
identified cancers that expressed elevated PIK3R3 by com-
paring PIK3R3 mRNA expression in the tumor samples
with their expression in control tissues from the same
patients. Two probe sets (202743_at and 211580_s_at)
interrogated PIK3R3 mRNA levels in these arrays, and
thus provided two independent read-outs of PIK3R3 gene
expression. PIK3R3 was significantly up-regulated in
cancer specimens (p < 0.05) and considered over-expressed
if the probe sets measured a greater than 2-fold increase in
PIK3R3 expression in the tumor sample compared to its
control. Thus, 19 (15%) or 12 (9.5%) samples exhibited
PIK3R3 over-expression according to different probe sets
(Figure 1).
Knockdown of PIK3R3 expression decreases cell
proliferation in GC cells
In order to understand the potential role of PIK3R3 in
GC, pathway analyses (Ingenuity IPA software) was per-
formed on genes co-regulated with PIK3R3. Pathway
analysis results highly suggested that PIK3R3 was
involved in cell growth and proliferation (Additional file 1:
Figure S1). To further investigate the potential effect of
PIK3R3 expression on cell proliferation, we first tested the
expression of PIK3R3 in 6 GC cell lines (Figure 2A).
HGC27, TMK1 and IM95 had significantly higher PIK3R3
expression than KATO III, AGS and MNK7. We next used
PIK3R3 siRNA to specifically knock down PIK3R3 protein
expression in HGC27 GC cells, and confirmed the knock-
down efficiency by Western blotting (Figure 2B). Knock-
down of PIK3R3 significantly decreased cell proliferation
based upon both crystal violet dye elution and BrdU in-
corporation assay (Figures 2C and D). Additionally,
PIK3R3 knockdown did not increase in the early apoptotic
Figure 1 PIK3R3 mRNA expression in 126 GC and paired non-neoplastic mucosa. (A) The fold change (log 2 value) of PIK3R3 mRNA expression
between the GC and their paired non-neoplastic mucosa. 12 (211580_s) or 19 (202743_at) cases showed more than 2 fold increase of PIK3R3.
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in HGC27 cells using another PIK3R3 siRNA (Additional
file 2: Figure S2).
Knockdown of PIK3R3 causes G0/G1 cell cycle arrest
Since PIK3R3 knockdown decreased cell proliferation, we
examined whether PIK3R3 knockdown also caused cell
cycle arrest at the G0/G1 phase by PI staining and FACS
analyses (Figure 3A). We observed that PIK3R3 knock-
down increased cells in G0/G1 arrest (59.8% vs. 48.4%).
Furthermore, the percentage of knockdown cells in G0/G1
cell cycle arrest increased when cells were deprived of
growth factors in culture media conditions (Figure 3A).
We also found increased G0/G1 cell cycle arrest in TMK1
GC cells (Additional file 3: Figure S3A). Taken together,
our results suggest that the main effect of PIK3R3 knock-
down is inhibition of cell proliferation by G0/G1 cell cycle
arrest rather than induction of cell apoptosis.
Knockdown of PIK3R3 decreases Rb phosphorylation and
cyclin D1 protein expression but does not affect basal
pAkt level
To understand better the functional role of PIK3R3 on cell
proliferation, we examined the expression of various mo-
lecular markers in the PIK3R3 knockdown cells. We found
reduced cyclin D1 levels and decreased phosphorylation of
Rb protein, both of which are associated with G0/G1 ar-
rest (Figure 3B and Additional file 3: Figure S3B). Expres-
sion of the cell proliferation marker, PCNA, also wasreduced (Figure 3B). Interestingly, phosphorylation of Akt
and mTOR was unaffected by PIK3R3 knockdown (Figure
3B and Additional file 3: Figure S3), suggesting that over-
expression of PIK3R3 does not primarily drive cell prolif-
eration through PI3K-pAkt signaling.
PIK3R3 over-expression can be regulated by PIK3CA
47 of the 126 paired GC and control tissues were compre-
hensively profiled on multi-omics platforms that measured
genome-wide mRNA expression, DNA copy number vari-
ation, and DNA methylation status. This multi-platform
allowed us to investigate whether structural genomic
changes or epigenetic regulation accounted for the up-
regulation of PIK3R3. However, we did not observe any
PIK3R3 gene amplification (i.e. average segments within
the gene were < 0.3, Additional file 4: Figure S4A), or
CpG island de-methylation in the GC with high
PIK3R3 mRNA expression (Additional file 4: Figure S4B).
Additionally, there was no consistent significant correl-
ation between either PIK3R3 copy number and mRNA
level, or CpG island methylation and the mRNA expres-
sion level (Additional file 4: Figure S4). Taken together,
these results indicate that some other mechanism
accounted for the increased PIK3R3 mRNA expression in
the high-expressing GC. Recently, several studies have
suggested that activated PI3K signaling induces the ex-
pression of PIK3R3 [23,24]. We thus investigated this pos-
sibility by assessing the correlation of mRNA expression of
PIK3R3 and PIK3CA, the p110 α catalytic subunit of PI3K.
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Figure 2 Knock down PIK3R3 by siRNA (sc-39124, Santa Cruz) inhibited the growth of HGC27 GC cells. (A) PIK3R3 mRNA level in 4 GC
lines measured by quantitative RT-PCR, and the relative PIK3R3 mRNA level was calculated by comparison against KATO III. Shown are the mean
+/− s.d. of triplicate samples. (B) Western blot of PIK3R3 knockdown in transfected cells. (C) Cell number (measured by optical density (O.D.)) after
knockdown by PIK3R3 siRNA. (D) DNA synthesis (BrdU incorporation) after knockdown of PIK3R3. The data in these experiments are expressed as
means ± S.D. from three independent experiments. The significance was assessed by paired student’s t-test. *P < 0.05 comparing knockdown with
control. (E) Cell death measured by Annexin-V/PI staining.
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positive correlation in 126 GC (Additional file 5: Figure
S5). Furthermore, PIK3CA inhibitor LY294002 treatment
decreased PIK3R3 mRNA and protein levels in HGC27
and IM95 cells (Figure 4).
Discussion
Although the roles of the PI3K catalytic subunit in
tumorigenesis is well established, current understanding
of the function of PI3K regulatory subunits such as
PIK3R3 is still limited. A previous study showed that
PIK3R3 gene had copy number gain in high-grade
glioma, and the Comparative Genomic Hybridization
(CGH) ratios for this locus were positively-correlated
with proliferation signatures [25]. Furthermore, the
IGF2-PIK3R3 signaling axis was involved in promotingthe growth of a subclass of highly aggressive human glio-
blastomas [9]. In this study, we compared PIK3R3
expression in 126 paired GC with non-neoplastic gastric
mucosa control tissues from the same patients, and
found that approximately 9.5% to 15% of GC showed
increased PIK3R3 expression. IPA pathway analysis sug-
gested a key role of PIK3R3 in cell proliferation. Knock-
down of PIK3R3 by siRNA decreased HGC27 GC cell
proliferation and induced cell cycle blockade at G0/G1.
Taken together, these results suggest that PIK3R3 stimu-
lates cell proliferation in GC and may be a potential
therapeutic target for a subgroup of GC.
PIK3R3 shares significant sequence identity with
PIK3R1 and PIK3R2 regulatory subunit in a proline-rich
motif and two Src homology 2 (SH2) domains; however,
it has an unique 24-residue NH2 terminus [26]. PIK3R3
Figure 3 Effects of PIK3R3 knockdown on cell cycle progression and cell signaling of HGC27 GC cells. (A) The effect of PIK3R3 knockdown
on cell cycle progression in HGC27 cells. The cells were cultured in complete medium for 48 h or 24 h followed by another 24 h in serum free
medium after siRNA transfection. The cells then were harvested for cell cycle analysis. The data are expressed as means ± S.D. from three
independent experiments. The significance was assessed by paired student’s t-test. *P < 0.05 and **P < 0.01 compared with control. (B) Western
blot analysis of the effects of PIK3R3 knockdown on cell signaling. Total cell extracts were probed with antibodies to cyclin D1, phospho-Rb
(p-Rb), PCNA, phospho-AKT (p-AKT), phospho-mTOR (p-mTOR), PIK3R3, actin (loading control) as indicated.
Figure 4 Effects of inhibition of PIK3CA signaling on the expression of PIK3R3. HGC27 and IM95 GC cells were seeded in complete medium
overnight. The complete medium was replaced by serum free medium, and PIK3CA inhibitor LY294002 was added. Total RNA or cell lysates were
harvested 24 h after treatment. The relative PIK3R3 mRNA level (A) or protein level (B) was measured by quantitative RT-PCR or western blot.
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amino acids of PIK3R3 (N24) are sufficient for binding
to Rb [27,28]. Ectopic expression of N24 also inhibited
cyclin D1 and E promoter activity and caused G0/G1
phase arrest in several cancer cell lines [27]. Likewise, in
the current study, knockdown of PIK3R3 caused G0/G1
cell cycle arrest in HGC27 and TMK1 GC cells. Consist-
ent with this observation, Rb phosphorylation, cyclin D1,
and PCNA protein levels also were decreased after
PIK3R3 knockdown. Interestingly, the pAkt levels did
not change after PIK3R3 knockdown. Additionally, when
PIK3R3 was overexpressed in AGS cells, a low PIK3R3-
expressing gastric cancer cell line, we did not observe
any significant change in phosphorylation of Akt (data
not shown). Taken together, these findings show that
both increased and decreased expression of PIK3R3 do
not affect pAkt levels in these cell lines under our ex-
perimental conditions. Of note, we have observed similar
effects in several colon cancer cell lines and MCF7 breast
cancer cells ([29]and unpublished data). This lack of
change in pAkt levels may be due to either preferential
nuclear localization of PIK3R3 [27] or low PIK3R3 ex-
pression relative to p85 regulatory subunit isoforms. In
contrast to our findings, Soroceau et al. found decreased
pAkt in G96 glioblastoma cells after PIK3R3 knockdown
which may be due to different experimental conditions
or different tissue origins of cell lines as PIK3R3 expres-
sion is high in the brain [9]. Nevertheless, our current
and previous studies suggest that PIK3R3 can promote
cell growth through a novel signaling pathway by regu-
lating Rb phosphorylation and cyclin D1.
Finally, we investigated the mechanism of PIK3R3
over-expression in GC. Zhang et al. found PIK3R3 was
over-expressed in ovarian cancer due to gene copy num-
ber gain [10]. However, no gene amplification or DNA
de-methylation of PIK3R3 gene was found in our set of
GC samples. Interestingly, Demoulin et al. found that
PDGF activated transcription factor SREBP-1 in a PI3K-
dependent manner [23], and ectopic expression of
SREBP-1 induces the expression of PIK3R3 in AG01518
human foreskin fibroblasts [24]. Therefore, these results
suggested that activated PI3K signaling could induce the
expression of PIK3R3. Indeed, we observed a positive
correlation between PIK3CA and PIK3R3 mRNA expres-
sion in our 126 GC samples. Furthermore, the PIK3CA
inhibitor, LY294002 decreased PIK3R3 expression in
HGC27 and IM95 GC cell lines. Our results thus provide
direct experimental evidence that PIK3R3 expression can
be regulated by PIK3CA.
Conclusion
The in silico and molecular biological approaches used
in the present study have provided a better understand-
ing of the expression and role of PIK3R3 in GC. Theidentification of PIK3R3 as a proliferation-promoting
factor in GC suggests that it might be a potential thera-
peutic target for a subset of GC.
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Additional file 1: Figure S1. IPA pathway analysis of PIK3R3 co-
regulated genes.
Additional file 2: Figure S2. Knock down PIK3R3 by siRNA (s16152,
Invitrogen) inhibited the growth of HGC27 GC cells. (A) Western blot of
PIK3R3 knockdown in transfected cells. (B) Cell number (measured by
optical density (O.D.)) after knockdown by PIK3R3 siRNA. (C) DNA
synthesis (BrdU incorporation) after knockdown of PIK3R3. The data in
these experiments are expressed as means ± S.D. from three independent
experiments. The significance was assessed by paired student’s t-test.
*P < 0.05 comparing knockdown with control. (D) Cell death measured by
Annexin-V/PI staining. These results using a different PIK3R3 siRNA gave
similar results shown in Figure 2.
Additional file 3: Figure S3. Effects of PIK3R3 knockdown on cell cycle
progression and cell signaling of TMK1 GC cells. (A) The effect of PIK3R3
knockdown on cell cycle progression in TMK1 cells. The cells then were
harvested 48 h after transfection followed by cell cycle analysis. The data
are expressed as means ± S.D. from three independent experiments. The
significance was assessed by paired student’s t-test. *P < 0.05 and
**P < 0.01 compared with control. (B) Western blot analysis of the effects
of PIK3R3 knockdown on cell signaling.
Additional file 4: Figure S4. The correlation between the PIK3R3 mRNA
expression (211580_s_at and 202743_at) and DNA copy number (A) or
promoter methylation status (B) in 47 paired GC and control tissue.
Additional file 5: Figure S5. The correlation between PIK3R3 and
PIK3CA mRNA expression in 126 GC specimens.
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